Skip to main content
. 2021 Oct 22;6(20):e152468. doi: 10.1172/jci.insight.152468

Figure 2. Target cell–bound PD-1 antibody ImmTAAI molecules exhibit superior inhibition of TCR complex signaling over PD-L1 ImmTAAI molecules.

Figure 2

(A and B) PD-1 antibody ImmTAAI molecules constructed using a panel of VHH PD-1 antibodies and an scFv PD-1 antibody (CA949) were tested in the HEK293T-A2/anti-CD3: Jurkat NFL PD-1 reporter assay as described in Figure 1 (n = 3 and representative of 3 independent experiments). (C and D) Representative VHH-based (H5) and scFv-based (CA949) ImmTAAI molecules were tested alongside the IgV–PD-L1 ImmTAAI in the HEK293T-A2/anti-CD3: Jurkat NFL PD-1 reporter assay, and data are plotted as described above (n = 3 and representative of 3 independent experiments). (E and F) PD-1 agonist ImmTAAI molecules were generated by fusing CA949 scFV antibody and IgV–PD-L1 to different TCRs against either gp100280–288 pHLA-A2 or PPI15–24 pHLA-A2. The ImmTAAI molecules were tested in the HEK293T-A2/anti-CD3: Jurkat NFL PD-1 reporter assay, using HEK293T-A2 target cells pulsed with the appropriate targeting peptide (n = 6 and representative of 2 independent experiments). All data are plotted as mean ± SD and were compared by 2-way ANOVA with repeated measures and Tukey’s or Sidak’s multiple-comparison test. **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.